newsfilter
← Latest News
GlobeNewswire·

Cosmos Health: A Company Transformed — 2026 Year-to-Date

COSM
  • H1 2026 revenue reached $36.91M (+29.7% YoY), following Q1 ($17.93M) & Q2 ($18.99M) records, with an annualized adjusted run-rate exceeding $75M.
  • FY2026 guidance reaffirmed at $90M+ revenue, alongside 2029 guidance of $200.6M revenue at a 32% CAGR from FY2025.
  • $8M ATW convertible note retired 12 months early, eliminating future conversions & dilution while strengthening the balance sheet.
  • Total liabilities reduced 13.3% to $40.79M, while stockholders' equity increased 12.2% to $20.67M in H1 2026.
  • 5.1M+ shares repurchased for ~$1.11M under the $5M authorization, with CEO Greg Siokas increasing personal holdings to 14.6M shares.
  • C-Scrub secured listings at Tesco (UK #1 retailer) & Superdrug (UK #2 retailer), plus expansion into hospital, surgical, & animal health channels.
  • Sky Premium Life global rollout includes exclusive Saudi Arabia agreement with Innova Healthcare (126K initial PO, 5M+ projected units), Qatar distribution, & full EU availability.
  • CCX0722 hydrogel patent filed in U.S., Europe, Australia, & Canada for the $190.6B weight management market.
  • 18 Series U.S. brands (Cur18, Liv18, Oliv18, Fort18) & NOOR Collagen launched with combined projected revenue of $22.7M+ at 70%+ gross margins.
  • $3.1M invested in digital assets (BTC + ETH) with Bitcoin holdings in a gain position, alongside ~$20M non-core assets identified for monetization.
  • Operating cash requirements reduced by >30% through revenue growth, AI integration, & cost reduction initiatives.
  • Zacks Small-Cap Research initiated coverage with a $4.50 price target, citing strong revenue trajectory & proprietary pipeline.
  • LOIs signed to acquire a $11.5M pharmacy distribution network & Doc Pharma S.A. to expand capacity & profitability.
  • AI deployed across order management, inventory, & customer operations to reduce operating expenses by up to 30%.
  • Advisory agreement signed with European Investment Bank for a €50M R&D program, potentially providing €25M in venture debt financing.